Artificial intelligence (AI) in drug discovery utilizes machine learning and deep learning algorithms to analyze large and complex datasets related to diseases, potential drug targets, and compounds libraries. AI helps pharmaceutical companies in target identification and validation, lead identification and optimization, and clinical trial optimization. AI speeds up the drug discovery process by automating time-consuming tasks such as compound screening, which enables companies to analyze a larger number of compounds and targets more efficiently as compared to human researchers. The global Artificial Intelligence in Drug Discovery Market is estimated to be valued at US$ 1266.7 Mn in 2023 and is expected to exhibit a CAGR of 6.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
One of the major market opportunities for AI in drug discovery is significant reduction in drug discovery costs. According to estimates, the average cost of developing a new drug ranges between US$ 800 million to US$ 2 billion. AI helps streamline the drug discovery process and reduces the costs significantly. AI enables automating tasks such as virtual high-throughput screening and clinical trial monitoring which not only accelerates the research process but also reduces costs substantially. It is estimated that AI can potentially reduce the drug discovery costs by more than 50% by automating repetitive tasks and enabling analysis of a larger number of compounds in lesser time. This cost reduction ability of AI technologies is driving their increasing adoption among pharmaceutical companies and is expected to boost the growth of artificial intelligence in drug discovery market during the forecast period.

Porter's Analysis
Threat of new entrants: Low- medium. High R&D costs and IP barriers to entry makes it difficult for new players to enter. However, low-cost is an opportunity for new entrants.

Bargaining power of buyers: Medium. Large pharmaceutical companies have bargaining power over smaller AI drug discovery startups. Buyers have options of collaborating with multiple AI providers.

Bargaining power of suppliers: Low. AI/ML algorithms and data are sourced from diverse online sources at low costs.

Threat of new substitutes: High. Alternative data modeling techniques and new therapeutic modalities pose threats to AI-based drug discovery.

Competitive rivalry: High. Significant players operating at global level results in high competition to gain leadership.

SWOT Analysis
Strengths: AI's ability to analyze vast amount of data and discover new insights. It helps accelerate drug discovery process at lower costs.

Weaknesses: Lack of authenticity of data used for modeling. Regulatory challenges on data privacy and ethics of AI systems.

Opportunities: Partnerships with pharma companies to test AI-generated hypotheses. Expanding scope to rare/neglected diseases and personalized medicine.

Threats: Bias and errors propagated in machine learning models. Slow adoption due to perceived job threats.

Key Takeaways
The Global Artificial Intelligence In Drug Discovery Market Share is expected to witness high growth.

Regional Analysis: The North American region dominates the market currently due to presence of major players and growing investments for research. The Asia Pacific region is expected fastest growing market due to increasing research funding and growing pharmaceutical industry.

Key players operating in the Artificial Intelligence in Drug Discovery market are Lenzing A.G., Aditya Birla Group, AkzoNobel N.V., Smartfiber AG, Nien Foun Fiber Co., Ltd., Invista , Baoding Swan Fiber Co. Ltd., Qingdao Textiles Group Fiber Technology Co., Ltd., China Bambro Textile (Group) Co. Ltd., Acegreen Eco-Material Technology Co. Ltd., China Populus Textile Ltd., and Acelon Chemicals & Fiber Corp. Collaboration of AI providers with pharmaceutical companies is critical for success. The global AI in drug discovery market relies on strengthening of data infrastructure and addressing regulatory challenges to realize its full potential.

Explorer more information on this topic, Please visit @ https://www.ukwebwire.com/artificial-intelligence-in-drug-discovery-market-size-and-share/

Get more insights on this topic: https://shoutingstars.com/pd-1-and-pd-l1-inhibitors-a-promising-cancer-immunotherapy